TAYSHA GENE THERAPIES INC (TSHA)
Health Care · Gene therapy / AAV-based therapeutics for rare neurological disorders · NASDAQ
Clinical-stage gene therapy company developing an AAV9-based treatment (TSHA-102) for Rett syndrome with early-stage clinical data showing functional gains in treated patients.
What TAYSHA GENE THERAPIES INC does
Taysha Gene Therapies is a clinical-stage biotechnology company developing AAV-based gene therapies for severe monogenic diseases of the central nervous system. The company's lead program, TSHA-102, is in development for the treatment of Rett syndrome, a rare neurodevelopmental disorder caused by MECP2 loss-of-function mutations. TSHA-102 is currently being evaluated in Phase 1/2 clinical trials (REVEAL and ASPIRE) with the goal of demonstrating safety and efficacy for approval across a broad patient population aged 2 years and older.
Themes: ["rare genetic disease / neurogenetic disorders","gene therapy / AAV-based therapeutics","CNS disorders","Rett syndrome"]
Fundamentals
- Price$6.57 as of 2026-07-09 close
- Market cap$2.1B as of 2026-07-10
- 1-year return+168.2% as of 2026-07-09 close
- Net margin-780.3% as of 2026-07-10
- ROE-56.1% as of 2026-07-10
- Debt / equity0.23 as of 2026-07-10
- Revenue growth (YoY)+3.4% as of 2026-07-10
- Revenue CAGR (3y)+57.5% SEC XBRL
- Beta1.25 as of 2026-07-10
Key risks (from latest filing)
["Clinical failure: TSHA-102 may not meet efficacy endpoints in pivotal trials (REVEAL Part B, ASPIRE), jeopardizing regulatory approval for Rett syndrome.","Manufacturing and supply: As a cell and gene therapy manufacturer, the company faces operational complexity, regulatory scrutiny, and potential supply chain constraints that could delay or limit treatment availability.","Capital requirements: The company is unprofitable with declining cash reserves ($276.6M as of Q1 2026 vs. $319.8M at year-end 2025) and will require additional funding to complete clinical development and commercialization, which may involve dilutive equity financing or unfavorable debt terms."]
Competitors & peers
- Regenxbio (RGNX)
- Solid Therapeutics (SLDT)
- Generation Bio
- Ionis Pharmaceuticals (IONS)
- Roche / Genentech (gene therapy programs)
Fundamentals: Finnhub, as of 2026-07-10. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-09.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date.